How much profit has Kamada made this year?
Kamada has made 15.05 M USD this year.
Kamada Net Income 2024
Kamada Net Income
15.05 M USD
Ticker
KMDA
ISIN
IL0010941198
WKN
A0JMEX
In 2024, Kamada's profit amounted to 15.05 M USD, a 81.69% increase from the 8.28 M USD profit recorded in the previous year.
The Kamada Net Income history
| YEAR | NET INCOME (undefined USD) |
|---|---|
| 2026e | 22.28 |
| 2025e | 18.18 |
| 2024e | 15.05 |
| 2023 | 8.28 |
| 2022 | -2.3 |
| 2021 | -2.2 |
| 2020 | 17.1 |
| 2019 | 22.3 |
| 2018 | 22.3 |
| 2017 | 6.9 |
| 2016 | -6.7 |
| 2015 | -11.3 |
| 2014 | -13.2 |
| 2013 | 0.4 |
| 2012 | 0.3 |
| 2011 | -3.7 |
| 2010 | -14.4 |
| 2009 | -21.3 |
| 2008 | -13.2 |
| 2007 | -21.5 |
| 2006 | -3 |
| 2005 | 1 |
| 2004 | 1.6 |
Kamada Revenue, EBIT, Net Income IL0010941198 · A0JMEX
3 years
5 years
10 years
25 Years
Max
Revenue
EBIT
Net Income
Details
Revenue, EBIT and Profit
ⓘUnderstanding Revenue, EBIT, and Income
Gain insights into Kamada, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Kamada from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Kamada’s net earnings, an ultimate measure of its financial health and profitability.
Yearly Analysis and Comparisons
Observe the yearly bars to understand the annual performance and growth of Kamada. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.
Utilizing Expectations for Investment
The expected values for the forthcoming years offer investors a glimpse into Kamada’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.
Investment Insights
Leveraging the comparison between Revenue and EBIT helps in assessing Kamada’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Kamada’s growth potential.
Kamada Revenue, EBIT and net profit per share
| Date | Kamada Revenue | Kamada EBIT | Kamada Net Income |
|---|---|---|---|
| 2026e | 195.83 M undefined | 24.72 M undefined | 22.28 M undefined |
| 2025e | 176.18 M undefined | 20.11 M undefined | 18.18 M undefined |
| 2024e | 163.68 M undefined | 17.52 M undefined | 15.05 M undefined |
| 2023 | 142.52 M undefined | 10.06 M undefined | 8.28 M undefined |
| 2022 | 129.3 M undefined | 4.5 M undefined | -2.3 M undefined |
| 2021 | 103.6 M undefined | -700,000 undefined | -2.2 M undefined |
| 2020 | 133.2 M undefined | 19.2 M undefined | 17.1 M undefined |
| 2019 | 127.2 M undefined | 22.8 M undefined | 22.3 M undefined |
| 2018 | 114.5 M undefined | 19.3 M undefined | 22.3 M undefined |
| 2017 | 102.8 M undefined | 7.4 M undefined | 6.9 M undefined |
| 2016 | 77.5 M undefined | -5.5 M undefined | -6.7 M undefined |
| 2015 | 69.9 M undefined | -11.4 M undefined | -11.3 M undefined |
| 2014 | 71.1 M undefined | -11.5 M undefined | -13.2 M undefined |
| 2013 | 70.6 M undefined | 3.7 M undefined | 400,000 undefined |
| 2012 | 72.7 M undefined | 4.2 M undefined | 300,000 undefined |
| 2011 | 59.5 M undefined | -2.5 M undefined | -3.7 M undefined |
| 2010 | 34.5 M undefined | -10.2 M undefined | -14.4 M undefined |
| 2009 | 14.5 M undefined | -15.8 M undefined | -21.3 M undefined |
| 2008 | 16.1 M undefined | -18 M undefined | -13.2 M undefined |
| 2007 | 12.6 M undefined | -15.3 M undefined | -21.5 M undefined |
| 2006 | 13.1 M undefined | -4 M undefined | -3 M undefined |
| 2005 | 11.5 M undefined | -2.8 M undefined | 1 M undefined |
| 2004 | 10.3 M undefined | -2.1 M undefined | 1.6 M undefined |
| Revenue | EBIT | Net Income | |
|---|---|---|---|
| 2004 | 10.3 M USD | -2.1 M USD | 1.6 M USD |
| 2005 | 11.5 M USD | -2.8 M USD | 1 M USD |
| 2006 | 13.1 M USD | -4 M USD | -3 M USD |
| 2007 | 12.6 M USD | -15.3 M USD | -21.5 M USD |
| 2008 | 16.1 M USD | -18 M USD | -13.2 M USD |
| 2009 | 14.5 M USD | -15.8 M USD | -21.3 M USD |
| 2010 | 34.5 M USD | -10.2 M USD | -14.4 M USD |
| 2011 | 59.5 M USD | -2.5 M USD | -3.7 M USD |
| 2012 | 72.7 M USD | 4.2 M USD | 300,000 USD |
| 2013 | 70.6 M USD | 3.7 M USD | 400,000 USD |
| 2014 | 71.1 M USD | -11.5 M USD | -13.2 M USD |
| 2015 | 69.9 M USD | -11.4 M USD | -11.3 M USD |
| 2016 | 77.5 M USD | -5.5 M USD | -6.7 M USD |
| 2017 | 102.8 M USD | 7.4 M USD | 6.9 M USD |
| 2018 | 114.5 M USD | 19.3 M USD | 22.3 M USD |
| 2019 | 127.2 M USD | 22.8 M USD | 22.3 M USD |
| 2020 | 133.2 M USD | 19.2 M USD | 17.1 M USD |
| 2021 | 103.6 M USD | -700,000 USD | -2.2 M USD |
| 2022 | 129.3 M USD | 4.5 M USD | -2.3 M USD |
| 2023 | 142.52 M USD | 10.06 M USD | 8.28 M USD |
| 2024e | 163.68 M USD | 17.52 M USD | 15.05 M USD |
| 2025e | 176.18 M USD | 20.11 M USD | 18.18 M USD |
| 2026e | 195.83 M USD | 24.72 M USD | 22.28 M USD |
Kamada stock margins IL0010941198 · A0JMEX
The Kamada margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Kamada. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Kamada.
3 years
5 years
10 years
25 Years
Max
Gross margin
EBIT margin
Profit margin
Details
Margin
ⓘUnderstanding Gross Margin
The gross margin, expressed as a percentage, delineates the gross profit made from the Kamada's sales revenue. A higher gross margin percentage indicates that the Kamada retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.
EBIT Margin Analysis
EBIT margin represents the Kamada's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.
Revenue Margin Insights
The revenue margin demonstrates the Kamada's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Kamada's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.
Interpreting Expectations
The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Kamada. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.
Comparative Analysis
Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Kamada's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.
Kamada Margin History
| Kamada Gross margin | Kamada Profit margin | Kamada EBIT margin | Kamada Profit margin |
|---|---|---|---|
| 2026e | 38.94 % | 12.62 % | 11.38 % |
| 2025e | 38.94 % | 11.42 % | 10.32 % |
| 2024e | 38.94 % | 10.71 % | 9.2 % |
| 2023 | 38.94 % | 7.06 % | 5.81 % |
| 2022 | 36.12 % | 3.48 % | -1.78 % |
| 2021 | 29.25 % | -0.68 % | -2.12 % |
| 2020 | 35.74 % | 14.41 % | 12.84 % |
| 2019 | 39.07 % | 17.92 % | 17.53 % |
| 2018 | 36.24 % | 16.86 % | 19.48 % |
| 2017 | 31.23 % | 7.2 % | 6.71 % |
| 2016 | 27.61 % | -7.1 % | -8.65 % |
| 2015 | 22.6 % | -16.31 % | -16.17 % |
| 2014 | 21.1 % | -16.17 % | -18.57 % |
| 2013 | 37.39 % | 5.24 % | 0.57 % |
| 2012 | 31.22 % | 5.78 % | 0.41 % |
| 2011 | 28.07 % | -4.2 % | -6.22 % |
| 2010 | 16.81 % | -29.57 % | -41.74 % |
| 2009 | -5.52 % | -108.97 % | -146.9 % |
| 2008 | 0.62 % | -111.8 % | -81.99 % |
| 2007 | 23.81 % | -121.43 % | -170.63 % |
| 2006 | 23.66 % | -30.53 % | -22.9 % |
| 2005 | 20.87 % | -24.35 % | 8.7 % |
| 2004 | 22.33 % | -20.39 % | 15.53 % |
| Gross margin | EBIT margin | Profit margin | |
|---|---|---|---|
| 2004 | 22.33 % | -20.39 % | 15.53 % |
| 2005 | 20.87 % | -24.35 % | 8.7 % |
| 2006 | 23.66 % | -30.53 % | -22.9 % |
| 2007 | 23.81 % | -121.43 % | -170.63 % |
| 2008 | 0.62 % | -111.8 % | -81.99 % |
| 2009 | -5.52 % | -108.97 % | -146.9 % |
| 2010 | 16.81 % | -29.57 % | -41.74 % |
| 2011 | 28.07 % | -4.2 % | -6.22 % |
| 2012 | 31.22 % | 5.78 % | 0.41 % |
| 2013 | 37.39 % | 5.24 % | 0.57 % |
| 2014 | 21.1 % | -16.17 % | -18.57 % |
| 2015 | 22.6 % | -16.31 % | -16.17 % |
| 2016 | 27.61 % | -7.1 % | -8.65 % |
| 2017 | 31.23 % | 7.2 % | 6.71 % |
| 2018 | 36.24 % | 16.86 % | 19.48 % |
| 2019 | 39.07 % | 17.92 % | 17.53 % |
| 2020 | 35.74 % | 14.41 % | 12.84 % |
| 2021 | 29.25 % | -0.68 % | -2.12 % |
| 2022 | 36.12 % | 3.48 % | -1.78 % |
| 2023 | 38.94 % | 7.06 % | 5.81 % |
| 2024e | 38.94 % | 10.71 % | 9.2 % |
| 2025e | 38.94 % | 11.42 % | 10.32 % |
| 2026e | 38.94 % | 12.62 % | 11.38 % |
Kamada Aktienanalyse
What does Kamada do?
Kamada Ltd is an Israel-based company specializing in the development and marketing of biopharmaceutical products for humans and animals. The company was founded in 1990 by a team of experienced executives and scientists from the biotech industry. Since its inception, Kamada has become a global leader in plasma fractionation and the production of antibodies and enzymes. The company is listed on the NASDAQ and the Tel Aviv Stock Exchange and has over 450 employees in its facilities in Israel and the USA. Kamada's business model is based on combining innovative science and technology to develop products and therapies for rare and severe diseases. The company is constantly working to improve its production processes to deliver more efficient and cost-effective products. Kamada operates in three divisions: human therapeutics, veterinary medicine, and plasma research. The human therapeutics division develops and markets products for the treatment of diseases such as alpha-1 antitrypsin deficiency, immunoglobulin deficiency, hemophilia, and other serious conditions. The veterinary medicine division offers products for the treatment of diseases in dogs, horses, and cows to veterinary professionals. The plasma research division focuses on developing technologies for the production of plasma derivatives and discovering new applications for plasma proteins. Kamada has a wide range of products on the market, including its flagship product Glassia, which is used to treat alpha-1 antitrypsin deficiency, a rare genetic disease that can affect the lungs. The company also produces intravenous immunoglobulin preparations for the treatment of immune deficiencies and other immune system disorders, as well as recombinant factor VIII for the treatment of hemophilia. In veterinary medicine, Kamada offers products such as Equine Seramune, designed for horses and used to treat life-threatening infections caused by bacteria found in the intestines of horses. The company also produces products for the treatment of mastitis, an infection of the milk ducts in cows, and gastrointestinal tract infections in dogs. Kamada takes pride in playing a leading role in plasma research and technology. The company's research has resulted in groundbreaking technologies that allow for the faster and more cost-effective production of important plasma proteins than was previously possible. Kamada works closely with other research institutions and companies to collaborate on solutions for severe and rare diseases. Over the years, Kamada has received numerous awards and recognition for its groundbreaking research and development work. The company is committed to continuing to develop innovative products and therapies to improve the lives of patients with rare and severe diseases. Overall, Kamada Ltd has experienced remarkable growth in recent years. It is a company that plays a leading role in the market for biopharmaceutical products based on top-notch scientific research and efficient technology. In the future, Kamada will undoubtedly continue to develop groundbreaking products and therapies to improve the lives of patients worldwide. Kamada ist eines der beliebtesten Unternehmen auf Eulerpool.com.Net Income Details
Understanding Kamada's Profit Margins
The profit margins of Kamada represent the net income earned after deducting all operational expenses, costs, and taxes from the revenue. This figure is a clear indicator of Kamada's financial health, operational efficiency, and profitability. Higher profit margins signify better cost management and income generation capabilities.
Year-to-Year Comparison
Evaluating Kamada's profit on a yearly basis can offer significant insights into its financial growth, stability, and trends. A consistent increase in profit suggests improved operational efficiency, cost management, or increased revenue, while a decrease may indicate rising costs, declining sales, or operational challenges.
Impact on Investments
Kamada's profit figures are critical for investors who are aiming to understand the company's financial standing and future growth prospects. Increased profits often lead to higher stock valuations, boosting investor confidence and attracting more investments.
Interpreting Profit Fluctuations
When Kamada’s profit increases, it often indicates enhanced operational efficiency or increased sales. In contrast, a decline in profit can signal operational inefficiencies, increased costs, or competitive pressures, necessitating strategic interventions to boost profitability.
Frequently Asked Questions about Kamada stock
How has the profit developed compared to last year?
The profit has increased by 81.69% compared to last year increased
What impact do the earnings have on the shareholders?
An increase in earnings is usually seen as a positive indicator for shareholders as it means that the company is generating profits.
How does Kamada publish its earnings?
Kamada publishes its earnings in the form of quarterly or annual reports.
Which financial indicators are included in the quarterly or annual reports?
The quarterly or annual reports contain information about sales and profit, cash flow, balance sheet, and other fundamentals.
Why is it important for investors to know the earnings of Kamada?
The profits of Kamada are an important indicator of the financial health of the company and can help investors decide whether they want to invest in the company or not.
How can one learn more about the earnings of Kamada?
You can learn more about the earnings of Kamada by reviewing the quarterly or annual reports or following the company presentations.
How much dividend does Kamada pay?
Over the past 12 months, Kamada paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Kamada is expected to pay a dividend of 0 USD.
What is the dividend yield of Kamada?
The current dividend yield of Kamada is .
When does Kamada pay dividends?
Kamada pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Kamada?
Kamada paid dividends every year for the past 0 years.
What is the dividend of Kamada?
For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.
In which sector is Kamada located?
Kamada is assigned to the 'Health' sector.
Wann musste ich die Aktien von Kamada kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Kamada from 11/9/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 11/9/2024.
When did Kamada pay the last dividend?
The last dividend was paid out on 11/9/2024.
What was the dividend of Kamada in the year 2023?
In the year 2023, Kamada distributed 0 USD as dividends.
In which currency does Kamada pay out the dividend?
The dividends of Kamada are distributed in USD.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von Kamada
Our stock analysis for Kamada Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Kamada Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.